Voltage-gated sodium channel family (Nav1.x)

The Voltage-gated sodium channel (Nav1.x) family comprises nine pore-forming alpha-subunit isoforms (Nav1.1 through Nav1.9) that are fundamental to the electrical excitability of neurons, cardiomyocytes, and skeletal muscle [3, 6, 14]. These transmembrane proteins mediate the rapid influx of sodium ions in response to membrane depolarization, which is the critical step for the initiation and propagation of action potentials [6, 14]. Genetic mutations in the SCN gene family encoding these channels lead to various channelopathies, including Dravet syndrome (epilepsy), Brugada syndrome (arrhythmia), and inherited erythromelalgia (chronic pain) [2, 4, 10, 13]. Therapeutically, Nav1.x channels are the primary targets for local anesthetics, anti-epileptic drugs, and Class I anti-arrhythmics, which generally function by blocking the ion-conducting pore or stabilizing the channel in an inactivated state [8, 13, 15]. A major challenge in targeting this family is achieving subtype selectivity to avoid systemic side effects, such as cardiac toxicity or neurological impairment, leading to significant research into selective inhibitors for specific isoforms like Nav1.7 and Nav1.8 for pain management [1, 3].

Other names

Voltage-gated sodium channelsVGSCsSCN familySodium channel alpha subunits

Pore blockade, stabilization of the inactivated state (fast or slow), and use-dependent inhibition.